GLP-1 receptor agonists in multiple sclerosis: a systematic review of preclinical and clinical evidence.
Mobeen Sajjad, Ahsan Sajjad, Rida Amer et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluated the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in multiple sclerosis (MS) through 15 studies, including preclinical and human data. The review found that GLP-1RAs reduced clinical severity in animal models and were associated with BMI reduction in humans, but did not affect EDSS or relapse rates. Most preclinical studies had a high risk of bias.
Key findings
- GLP-1RAs reduced clinical severity in EAE models through various neuroprotective mechanisms.
- In humans, GLP-1RA use was associated with BMI reduction and vitamin D augmentation.
- No change in EDSS or relapse rate was observed in human studies.
- Pharmacovigilance indicated inverse reporting odds ratios for semaglutide, dulaglutide, and liraglutide.
Why it matters
Understanding the potential benefits and safety of GLP-1RAs in MS could inform future treatment strategies, especially given their metabolic benefits without neurological harm. This evidence may guide clinicians in considering GLP-1RAs for MS patients.
What to keep in mind
Most preclinical studies were assessed as having a high risk of bias, and human studies were of moderate to high quality.